Welcome Visitor, Sign Up for Free!

Hospira Recalls Cancer Drugs With Defected Glass Vials

scientists examining glass vials

A defect in the glass vials for the drugs Carboplatin, Cytarabine, Methotrexate, and Paclitaxel has mandated a 19 lot recall.

On June 27, 2012 Hospira Inc. released a letter to consumers about the recall of certain cancer, psoriasis, and rheumatoid arthritis treatments due to a defect in the glass vials used to contain the products. According to the statement, small particles had become embedded within the glass vials of Carboplatin, Cytarabine, Methotrexate, and Paclitaxel injection products resulting in a voluntary recall of 19 lots of these medications.

Since the issuance of the recall, Hospira has notified the U.S. Food and Drug Administration of further recall information. On July 13, 2012 Hospira announced a recall update for the defected vials of  the cancer treatments. The company highlights the possible risk of the particles in the glass vials to fall into the medicine and become injected into a patient which can cause serious side effects such as:

  • increased bleeding or unusual bruising
  • swelling, itchiness or a rash
  • tension or pain in the chest
  • respiratory complications

Patients should not use the recalled products but rather end use, quarantine the item and contact Stericycle by calling 1-888-628-0734. Hospira Customer Care may be reached at 1-877-976-7747 to schedule a replacement of the product.

No adverse reactions have been made known to the FDA nor Hospira at this point. However, any patient who has mistakenly used a recalled product and developed an adverse reaction should contact the FDA MedWatch Program for more information. Reach the program by faxing your information to 1-800-FDA-0178, mailing a case form at www.fda.gov/Safety/Recalls/, or visiting https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm.